- Home
- PHAT
as 08-01-2025 4:00pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Upcoming Earnings Alert:
Get ready for potential market movements as Phathom Pharmaceuticals Inc. PHAT prepares to release earnings report on 07 Aug 2025.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 640.9M | IPO Year: | 2019 |
| Target Price: | $16.40 | AVG Volume (30 days): | 937.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $19.71 | Next Earning Date: | 08-07-2025 |
| Revenue: | $81,859,000 | Revenue Growth: | 3055.70% |
| Revenue Growth (this year): | 195.03% | Revenue Growth (next year): | 106.77% |
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Topper James N | PHAT | Director | May 21 '25 | Buy | $3.86 | 3,780 | $14,609.32 | 59,403 | |
| Topper James N | PHAT | Director | May 13 '25 | Buy | $3.24 | 7,420 | $24,462.49 | 59,403 | |
| Topper James N | PHAT | Director | May 9 '25 | Buy | $3.28 | 48,203 | $152,916.63 | 59,403 | |
| Parikh Asit | PHAT | Director | May 6 '25 | Buy | $2.50 | 10,000 | $24,984.50 | 90,500 |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
MT Newswires
2 months ago
Phathom Pharmaceuticals' Heartburn Drug Receives Regulatory Exclusivity in FDA Orange Book Update
GlobeNewswire
2 months ago
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
Zacks
2 months ago
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
MT Newswires
2 months ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
2 months ago
Top Midday Gainers
MT Newswires
2 months ago
Sector Update: Health Care Stocks Advance in Afternoon Trading
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.